Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

KJ Falkenberg, RW Johnstone - Nature reviews Drug discovery, 2014 - nature.com
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are
often caused by genetic defects that result in functional deregulation of epigenetic proteins …

[HTML][HTML] Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective

V Kumar, S Kundu, A Singh, S Singh - Current neuropharmacology, 2022 - ncbi.nlm.nih.gov
Neurodegenerative diseases are a group of pathological conditions that cause motor inc-
ordination (jerking movements), cognitive and memory impairments result from …

The epigenetics of aging and neurodegeneration

R Lardenoije, A Iatrou, G Kenis, K Kompotis… - Progress in …, 2015 - Elsevier
Epigenetics is a quickly growing field encompassing mechanisms regulating gene
expression that do not involve changes in the genotype. Epigenetics is of increasing …

[HTML][HTML] The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models

V Chopra, L Quinti, J Kim, L Vollor, KL Narayanan… - Cell reports, 2012 - cell.com
Summary Inhibition of sirtuin 2 (SIRT2) deacetylase mediates protective effects in cell and
invertebrate models of Parkinson's disease and Huntington's disease (HD). Here we report …

[HTML][HTML] Histone deacetylases (HDACs) and brain function

CH Volmar, C Wahlestedt - Neuroepigenetics, 2015 - Elsevier
Modulation of gene expression is a constant and necessary event for mammalian brain
function. An important way of regulating gene expression is through the remodeling of …

[HTML][HTML] When good kinases go rogue: GSK3, p38 MAPK and CDKs as therapeutic targets for Alzheimer's and Huntington's disease

SR D'Mello - International Journal of Molecular Sciences, 2021 - mdpi.com
Alzheimer's disease (AD) is a mostly sporadic brain disorder characterized by cognitive
decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex …

Targets for future clinical trials in Huntington's disease: what's in the pipeline?

EJ Wild, SJ Tabrizi - Movement Disorders, 2014 - Wiley Online Library
The known genetic cause of Huntington's disease (HD) has fueled considerable progress in
understanding its pathobiology and the development of therapeutic approaches aimed at …

Epigenetic therapy for F riedreich ataxia

E Soragni, W Miao, M Iudicello, D Jacoby… - Annals of …, 2014 - Wiley Online Library
Objective To investigate whether a histone deacetylase inhibitor (HDACi) would be effective
in an in vitro model for the neurodegenerative disease Friedreich ataxia (FRDA) and to …

Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders

LM Valor, J Viosca, JP Lopez-Atalaya… - Current …, 2013 - ingentaconnect.com
Neuropsychiatric pathologies, including neurodegenerative diseases and
neurodevelopmental syndromes, are frequently associated with dysregulation of various …

[HTML][HTML] The role of altered protein acetylation in neurodegenerative disease

F Kabir, R Atkinson, AL Cook, AJ Phipps… - Frontiers in Aging …, 2023 - frontiersin.org
Acetylation is a key post-translational modification (PTM) involved in the regulation of both
histone and non-histone proteins. It controls cellular processes such as DNA transcription …